Phase IV study of IFN beta-1a (30 mcg/week) in Japanese patients with RRMS.
ARR decreased and EDSS score improved during the 2-year treatment period.
There were no new safety concerns noted during the study.
Dose titration slightly reduced influenza-like symptoms at early timepoints.
IFN beta-1a can be used effectively and safely in Japanese patients with RRMS.